World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
98
Citations
50495
World Ranking
8762
National Ranking
4519

Overview

Adam Brufsky is affiliated with the University of Pittsburgh in the United States and has a research focus primarily in the fields of Medicine and Biochemistry, Genetics, and Molecular Biology. Their work spans multiple subfields, notably Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Genetics, and Infectious Diseases.

The scientist has contributed extensively to research on advanced breast cancer therapies and related topics. Their main areas of investigation include:

  • Advanced Breast Cancer Therapies
  • Breast Cancer Treatment Studies
  • HER2/EGFR in Cancer Research
  • Cancer Treatment and Pharmacology
  • Cancer Genomics and Diagnostics
  • SARS-CoV-2 and COVID-19 Research
  • Chronic Lymphocytic Leukemia Research

Brufsky's publications have appeared frequently in recognized medical and oncology journals. The top venues for their work include:

  • Cancer Research
  • Journal of Clinical Oncology
  • Annals of Oncology
  • Clinical Cancer Research
  • ESMO Open

Among the recent and notable papers associated with the field of breast cancer and oncology are:

  • "Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer" (2021), New England Journal of Medicine
  • "Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study" (2020), The Lancet Oncology
  • "Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial" (2020), Journal of Clinical Oncology
  • "TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes" (2020), Journal of Clinical Oncology
  • "Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer" (2022), Annals of Oncology

Collaboration is a significant aspect of Brufsky's research, with frequent co-authors including Hope S. Rugo, Sara A. Hurvitz, Joyce O'Shaughnessy, Lynn McRoy, and Rachel M. Layman. These collaborators indicate active engagement in oncology and breast cancer research communities.

Best Publications

  • Comprehensive molecular portraits of human breast tumours

    Daniel C. Koboldt;Robert S. Fulton;Michael D. McLellan;Heather Schmidt

  • Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer

    Joseph A. Sparano;Robert J. Gray;Della F. Makower;Kathleen I. Pritchard

  • Prospective Validation of a 21-Gene Expression Assay in Breast Cancer

    J. A. Sparano;R. J. Gray;D. F. Makower;K. I. Pritchard

  • RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer

    Nicholas J. Robert;Véronique Diéras;John Glaspy;Adam M. Brufsky

  • Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

    Aditya Bardia;Sara A Hurvitz;Sara M Tolaney;Delphine Loirat

  • The CAG repeat within the androgen receptor gene and its relationship to prostate cancer.

    Edward Giovannucci;Meir J. Stampfer;Krishna Krithivas;Myles Brown

  • Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer

    Nancy U Lin;Véronique Diéras;Devchand Paul;Dominique Lossignol

  • Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

    Sandra M Swain;Sandra M Swain;David Miles;Sung-Bae Kim;Young-Hyuck Im

  • Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT.

    Stephen Chia;William Gradishar;Louis Mauriac;Jose Bines

  • Bevacizumab added to neoadjuvant chemotherapy for breast cancer

    Harry D. Bear;Gong Tang;Priya Rastogi;Charles E. Geyer

  • Seven-Year Follow-Up Assessment of Cardiac Function in NSABP B-31, a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel (ACP) With ACP Plus Trastuzumab As Adjuvant Therapy for Patients With Node-Positive, Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

    Edward H. Romond;Jong Hyeon Jeong;Priya Rastogi;Sandra M. Swain

  • Zoledronic Acid Inhibits Adjuvant Letrozole–Induced Bone Loss in Postmenopausal Women With Early Breast Cancer

    Adam Brufsky;W. Graydon Harker;J. Thaddeus Beck;Robert Carroll

  • RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

    Adam M. Brufsky;Sara Hurvitz;Edith Perez;Raji Swamy

  • Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer.

    Joseph A. Sparano;Robert J. Gray;Peter M. Ravdin;Della F. Makower;Della F. Makower

  • Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With >= 2 HER2-Directed Regimens: Phase III NALA Trial

    Cristina Saura;Mafalda Oliveira;Yin-Hsun Feng;Ming-Shen Dai

  • Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial

    André Robidoux;Gong Tang;Priya Rastogi;Charles E Geyer

  • Cognitive impairment associated with adjuvant therapy in breast cancer.

    Catherine M. Bender;Susan M. Sereika;Sarah L. Berga;Victor G. Vogel

  • Central Nervous System Metastases in Patients with HER2-Positive Metastatic Breast Cancer: Incidence, Treatment, and Survival in Patients from registHER

    Adam M. Brufsky;Musa Mayer;Hope S. Rugo;Peter A. Kaufman

  • TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes.

    Nadine M Tung;Nadine M Tung;Mark E Robson;Steffen Ventz;Cesar A Santa-Maria

  • Practical guidance for the management of aromatase inhibitor-associated bone loss

    P. Hadji;J.-J. Body;M.S. Aapro;A. Brufsky

Frequent Co-Authors

Hope S. Rugo
Hope S. Rugo University of California, San Francisco
Sandra M. Swain
Sandra M. Swain Georgetown University Medical Center
Steffi Oesterreich
Steffi Oesterreich University of Pittsburgh
Louis Fehrenbacher
Louis Fehrenbacher Kaiser Permanente
Nancy E. Davidson
Nancy E. Davidson University of Washington
Joyce O'Shaughnessy
Joyce O'Shaughnessy Baylor University Medical Center
Susan M. Sereika
Susan M. Sereika University of Pittsburgh
Soonmyung Paik
Soonmyung Paik Yonsei University
Charles E. Geyer
Charles E. Geyer University of Pittsburgh
Sara A. Hurvitz
Sara A. Hurvitz Fred Hutchinson Cancer Research Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those considering studying Medicine in the USA, a variety of related online degrees and alternative career pathways can complement or enhance your primary education. Healthcare is a vast field, and many related disciplines offer outstanding career prospects alongside flexibility and affordability.

Pursuing a Master’s in Healthcare Administration (MHA) is a popular option for students aiming to move into managerial or leadership positions within the healthcare sector. Numerous affordable mha online programs allow you to earn this degree while continuing your current professional or personal commitments.

If your interests lie in advanced nursing practices, you may consider enrolling in cheap dnp online programs to achieve a Doctor of Nursing Practice. This high-level credential can open roles in clinical leadership, education, or specialized care.

Pharmacists are essential members of the healthcare team. Those looking to enter this profession can explore pharm d online programs for an accessible path to a Doctor of Pharmacy degree from accredited institutions.

For a career at the intersection of healthcare, technology, and administration, consider rhia certification programs online. These programs cover skills necessary for managing patient data and healthcare information systems—an increasingly vital role in modern medicine.

Best Scientists Citing Adam Brufsky

Trending Scientists

Recently Published Articles